L-nucleosides incorporated into polymeric structure for stabiliz

Details L-nucleosides incorporated into polymeric structure for stabiliz L-nucleosides incorporated into polymeric structure for stabiliz

1997-01-24

1998-09-15

Wilson, James O.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 2531, 536 2532, 536 2534, 536124, 536126, C07H 100, C07H 2104

Patent

active

058080406

DESCRIPTION:

BRIEF SUMMARY
This invention is in the area of methods for the treatment of hepatitis B virus (also referred to as "HBV") and Epstein-Bar Virus (referred to as "EBV") that includes administering an effective amount of one or more of the active compounds disclosed herein, or a pharmaceutically acceptable derivative or prodrug of one of these compounds.


BACKGROUND OF THE INVENTION

Hepatitis B virus has reached epidemic levels worldwide. After a two to six month incubation period in which the host is unaware of the infection, HBV infection can lead to acute hepatitis and liver damage, that causes abdominal pain, jaundice, and elevated blood levels of certain enzymes. HBV can cause fulminant hepatitis, a rapidly progressive, often fatal form of the disease in which massive sections of the liver are destroyed. Patients typically recover from acute viral hepatitis. In some patients, however, high levels of viral antigen persist in the blood for an extended, or indefinite, period, causing a chronic infection. Chronic infections can lead to chronic persistent hepatitis. Patients infected with chronic persistent HBV are most common in developing countries. By mid-1991, there were approximately 225 million chronic carriers of HBV in Asia alone, and worldwide, almost 300 million carriers. Chronic persistent hepatitis can cause fatigue, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.
In western industrialized countries, high risk groups for HBV infection include those in contact with HBV carriers or their blood samples. The epidemiology of HBV is in fact very similar to that of acquired immunodeficiency syndrome, which accounts for why HBV infection is common among patients with AIDS or HIV-associated infections. However, HBV is more contagious than HIV.
HBV is second only to tobacco as a cause of human cancer. The mechanism by which HBV induces cancer is unknown, although it is postulated that it may directly trigger tumor development, or indirectly trigger tumor development through chronic inflammation, cirrhosis, and cell regeneration associated with the infection.
The Epstein-Barr virus (EBV) is a member of the genus Lymphocryptovirus, which belongs to the subfamily gammaherpesvirinae. It is notably lymphotropic. EBV has the classic structure of herpesviruses, viz., its double-stranded DNA genome is contained within an icosapentahedral nucleocapsid, which, in turn, is surrounded by a lipid envelope studded with viral glycoproteins. An amorphous tegument protein occupies the space between the envelope and the nucleocapsid.
All human herpesviruses infect and replicate within lymphocytes to some extent, but EBV does so efficiently. Most importantly, the pathogenesis and host responses to infection with EBV are more dependent upon lymphocytic infection than is evident with the other human herpesviruses.
EBV is now recognized as a cause of B-cell lymphoproliferative diseases, and has been linked to a variety of other severe and chronic illnesses, including a rare progressive mononucleosis-like syndrome and oral hairy leukoplakia in AIDS patients. The suggestion that EBV is a major cause of chronic fatigue has not withstood scrutiny.
EBV is primarily transmitted through the saliva, although some infections are transmitted by blood transfusion. More than 85% of patients in the acute phases of infectious mononucleosis secrete EBV.
EBV has been associated with cancer. At least two groups of patients are at risk for development of EBV-associated lymphomas: those who have received transplants of kidney, heart, bone marrow, liver, or thymus under the cover of immunosuppressive therapy, and patients with AIDS. EBV-associated cancers include Burkitt's Lymphoma and Nasopharyngeal Carcinoma.
In light of the fact that hepatitis B virus and Epstein-Barr virus have severe and often tragic effects on the infected patient, there remains a strong need to provide new effective pharmaceutical agents to treat humans infected with the viruses that have low toxicity to the host.
Therefore, it is an object of the present i

REFERENCES:
patent: 3116268 (1963-12-01), Hunter
patent: 3553192 (1971-01-01), Gauri
patent: 4000137 (1976-12-01), Dvonoch et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 4968674 (1990-11-01), Taniyama et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5071983 (1991-12-01), Koszalka et al.
patent: 5089500 (1992-02-01), Daluge
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Koszalka et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5215971 (1993-06-01), Datema et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5246924 (1993-09-01), Fox et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta
patent: 5409906 (1995-04-01), Datema et al.
patent: 5432165 (1995-07-01), Adair et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5446029 (1995-08-01), Eriksson et al.
patent: 5466806 (1995-11-01), Belleau et al.
Asseline, U., et al., "Synthesis and Physiocochemical Properties of Oligonucleotides Built with Either .alpha.-L or .beta.-L Nucleotides Units and Covalently Linked to an Acridine Derivative," Nucleic Acids Research, 19(15):4067-4074 (1991).
Balzarini, J., et al., "Potent and Selective Anti-HTLV-III/LAV Activity of 2',3'-Dideoxycytidinene, . . . ," Bioch. and Bioph. Res. Comm. 140(2):735-742 (1986).
Beach, J.W., et al., "Synthesis of EnantiomericallyPure Chem. 57:2217-2219 (1992).
Belleau, B., et al., "Design and Activity of a Novel Class of Nucleoside Analogs . . . ," Intl. Conf. on AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
Bouffard, D.Y., et al., "Kinetic Studies on 2',2'-Difluorodeoxycytidine(Gemcitibine) with Purified Human Deoxycytidine Kinase and Cytidine Deaminase," Biochem. Pharmacol. 45(9): 1857-1861 (1993).
Carter, et al., "Activities of (-)-Carbovir and 3'-Azido-3'Deoxythymidine Against Human Immunodeficiency Virus In Vitro," Antimicrobial Agents and Chemotherapy 34(6):1297-1300 (1990).
Chang, C-N., et al., "Biochemical Pharmacology of (+) and (-)-2',3'-Dideoxy-3'Thioacytidine as Anti-Hepatitis B Virus Agents," J. Biol. Chem. 267(31):22414-22420 (1992).
Chang, Chien-Neng, et al., "Deoxycytidine Deaminase-resistant Steroisomer is the Active Form of . . . ," J. Bio. Chem., 267(20):13938-13942 (1992).
Chang, Chungming, et al., "Production of Hepatitis B Virus in vitro by Tansient Expression . . . ," The EMBO J. 6(3):675-680 (1987).
Chen, Chin-Ho, et al., "Delayed Cytotoxicity and Selective Loss of Mitochondria DNA in Cells . . . ," J. Bio. Chem. 264(2):11934-11937 (1989).
Cheng, Y.C., et al., "Human Deoxycytidine Kinase Purification and Characterization . . . ," Biochim. Biophys. Acta. 481:481-492 (1977).
Chottiner, E.G., "Cloning and Expression of Human Deocytidine Kinase cDNA," Proc. Natl. Sci. USA, 88:1531-1535 (1991).
Chu, C.K., et al., "An Efficient Total Synthesis of 3'-Azido-3'Deoxythiymidine (AZT)and 3'-Azido-2',3'-Dideoxyuridine (AZDDU, CS-87) . . . ," Tetrahedron Lett., 29(42):5349-5352 (1988).
Chu, et al., "Comparative Activity of 2',3'-Saturated and Unsaturated Pyrimidine and Purine Nucleosides . . . ," Biochem. Pharm. 37(19):3543-3548 (1988).
Chu, et al., "Structure-Activity Relationships of Pyrimidine Nucleosides as Antiviral Agents . . . ," J. Med. Chem. 32:612-617 (1989).
Chu, C.K., et al., "2'-Fluoro-5-Methyl-.beta.-L-Arabinofuranosyluracil as a Novel Antiviral Agent for Hepatitis B . . . ," Antimicrob. Agents Chemother., 39(4):979-981 (1995).
Coates, J., et al., "The Separated Enaniomers of 2'-deoxy-3'-thiacytidine (BCH-189) . . . ," Antimicrob. Agents

Affiliated with

Also associated with

Rating

L-nucleosides incorporated into polymeric structure for stabiliz does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with L-nucleosides incorporated into polymeric structure for stabiliz, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and L-nucleosides incorporated into polymeric structure for stabiliz will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-89097